Organization
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
21 abstracts
Abstract
Primary localized malignant PEComa treated with surgery: A report of a large series of patients treated in a referral institution.Org: Unit of Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy,
Abstract
Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.Org: Institut du Cancer Paris CARPEM, APHP-INSERM U1149 Universite Paris Diderot, Digestive Oncology Department, APHP.Centre - Université Paris Cité, Hôpital Européeen G. Pompidou,
Abstract
Biology and performance of pre- and post-pembrolizumab (Pembro) vesical imaging–reporting and data system (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline.Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Milano, Veracyte, Inc., IRCCS Ospedale San Raffaele, Radiology Unit,
Abstract
Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.Org: Memorial Sloan Kettering Cancer Center, Sorbonne University and Saint-Antoine Hospital, Pitié Salpêtrière Hospital, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.Org: Humanitas University, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, IRCCS Humanitas Research Hospital, Rozzano, Italy, Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Hospital Clínic Barcelona,
Abstract
Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.Org: Moores Cancer Center, UC San Diego Health, University of California San Diego, La Jolla, CA, Institut Curie, Saint Cloud, France, Paris, France,
Abstract
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in CheckMate 238.Org: New York University School of Medicine, Bristol Myers Squibb, Istituto Nazionale Tumori IRCCS Fondazione Pascale, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy,
Abstract
Prognostic factors of early mortality in children and adolescents enrolled in oncology trials with a dose-finding part in the era of targeted and immune therapies: An Innovative Therapies for Children with Cancer (ITCC) study.Org: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Prinses Máxima Center for Pediatric Oncology, Institute Gustave Roussy, SIREDO Oncology Center, Institut Curie, Saint Cloud, France,
Abstract
Phase II study of the efficacy of retifanlimab (Rf) (INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis.Org: Medical Oncology Group, Institut Català d'Oncologia (ICO) L ́Hospitalet and Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Hospital Universitario 12 de Octubre (CIBERONC), IRCCS Ospedale San Raffaele,
Abstract
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Medicine, Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Harvard Medical School, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Outcome of patients (PTS) with advanced epithelioid hemangioendothelioma (EHE) after failure on sirolimus (S).Org: Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Istituto Oncologico Veneto IOV-IRCCS, Department of Medical Oncology, Fondazione Policlinico Campus Bio-Medico, Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy,
Abstract
Trabectedin failure-free survival (TFFS) after resuming trabectedin (T) in advanced myxoid liposarcoma (MLPS) patients.Org: Italian National Cancer Institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Adult Mesenchymal Tumour & Rare Cancer Medical Oncology Unit, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Surgery, Brigham and Women's Hospital, Boston, MA,
Abstract
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Dana-Farber Cancer Institute, MD Anderson Cancer Center, University of Lille,
Abstract
Association of HRD ovarian cancer by RAD51 with hot immune microenvironment: Translational analyses of MITO 16A/MaNGO-OV2 trial.Org: University of Parma, Department of Molecular Medicine and Surgery, Federico II University of Naples, Cannizzaro Hospital of Catania, University Hospital of Parma,
Abstract
Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).Org: Cliniques Universitaires Saint-Luc, Department of Drug Development and Innovation (D3i), Institut Curie, Saint Cloud, France, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development,
Abstract
Clinical characterization of responders to first line (chemo)immunotherapy in platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).Org: Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Hemato-Oncology (DIPO), University of Milano, European Institute of Oncology, Division of Early Drug Development, Head and Neck Cancer Medical Department,
Abstract
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: The IMMINENT study.Org: University of Verona, Oncology Section, Azienda Ospedaliera Universitaria Integrata di Verona, Ospedale San Bortolo Azienda ULSS8 Berica - Distretto Est, Santa Chiara Hospital, Trento, Italy, Policlinico Universitario Gaspare Rodolico,
Abstract
NALIRIFOX vs FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line treatment of advanced pancreatic cancer: An individual patient data pooled analysis of phase 3 registration trials.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Head and Neck Cancer Medical Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan,
Abstract
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.Org: Hôpital Européen Georges-Pompidou, Paris, Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, University Hospital 12 de Octubre, LMU Munich,
Abstract
Combinatorial immune biomarkers of efficacy on buparlisib and paclitaxel in patients with SCCHN: BERIL-1 sub-analysis.Org: Adlai Nortye USA Inc., Adlai Nortye Biopharma, Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Hemato-Oncology, University of Milan, and Division of Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy,
Abstract
Italian report of expanded access for nab-sirolimus in patients with malignant perivascular epithelioid cell tumor (PEComa).Org: Instituto Tumori Milano, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto Nazionale Tumori Pascale, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy,